Snapshot from Jul 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Teva advances TEV-408 to Phase 2b
Business clinical trial update

Teva advances TEV-408 to Phase 2b

Analysis based on 7 articles · First reported Jul 07, 2026 · Last updated Jul 07, 2026

Sentiment
40
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 1b data and advancement to Phase 2b strengthen Teva's immunology pipeline and support its Pivot to Growth strategy, potentially boosting investor confidence. The $500 million funding from Royalty Pharma de-risks development costs, while the Fast Track designation from the FDA accelerates regulatory pathway.

Pharmaceuticals Biotechnology
Event Summary

Sun Pharma announced plans to advance its investigational anti-IL-15 monoclonal antibody TEV-408 into a Phase 2b study for vitiligo in Q4 2026, following encouraging Phase 1b results showing improvements in skin pigmentation and no safety signals. Nearly 75% of patients reported improvement in facial vitiligo. TEV-408 is also being studied for celiac disease and has Fast Track designation from the U.S. FDA. Teva has secured up to $500 million in R&D funding from Royalty Pharma to support the program.

Key Actions
70 Sun Pharma announced plans to advance
60 Sun Pharma secured R&D funding Royalty Pharma
50 United States — Food and Drug Administration granted Fast Track designation Sun Pharma
Entities Involved
stock
Sun Pharma
Teva is the developer of TEV-408 and announced the Phase 2b advancement, which supports its pipeline and growth strategy, positively impacting its stock.
Importance 100.0 Sentiment 60.0
stock
Royalty Pharma
Royalty Pharma provides up to $500 million in R&D funding for TEV-408, sharing in potential future royalties.
Importance 40.0 Sentiment 30.0
govactor
United States — Food and Drug Administration
The FDA granted Fast Track designation for TEV-408 in celiac disease, supporting accelerated development.
Importance 30.0 Sentiment 0.0
per
Richard Francis
As CEO, Richard Francis highlighted TEV-408 as a key innovative program in Teva's pipeline.
Importance 20.0 Sentiment 0.0
per
Eric Hughes
As Chief Medical Officer, Eric Hughes expressed confidence in the IL-15 pathway and the program's potential.
Importance 15.0 Sentiment 0.0
cnt
United States
The U.S. is a key market for Teva; the FDA's Fast Track designation facilitates development.
Importance 10.0 Sentiment 0.0
Relationships
Sun Pharma related ↔ United States — Food and Drug Administration
Sun Pharma related ↔ United States
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.